Reinsurance Group of America enters the week of August earnings with its strongest monthly price performance in some time — up 12% over 30 days to $230.22 — and two fresh analyst target increases arriving back-to-back, putting the Street's conviction on full display just ahead of the August 6 Q2 print.
The analyst story is the clearest signal this week. Barclays raised its target to $278 on July 7, maintaining its Overweight rating, while UBS followed on July 8 with a lift to $236, holding Neutral. Both moves came after the stock had already rallied hard, suggesting these are catch-up revisions rather than early calls. The broader Street picture reinforces the bullish lean: the consensus mean target sits at $255, implying roughly 11% further upside from current levels. JPMorgan and Wells Fargo both carry Overweight ratings and have raised targets at various points this year. The lone dissent comes from Morgan Stanley, which holds Equal-Weight and last moved its target to $223 in March — well below where the stock is now. The bull case centers on improving new money yields, a rising ROE target of 13–15%, and steady book value growth. Bears point to Asia Pacific weakness, benefit ratio pressure, and higher-than-expected corporate expenses as the drags most likely to disappoint on August 6.
Short positioning tells a quiet story, and rightly so. Short interest is running at just 1.7% of the free float — low by any measure — and has actually eased about 2% over the past week even as the stock climbed. Borrow availability is essentially uncapped, with availability at the lending-pool ceiling, meaning there is no mechanical pressure on short sellers and no squeeze dynamic worth flagging. Cost to borrow has drifted down 12% on the week to around 0.50%, cheap enough that maintaining a short position costs almost nothing. Options traders are equally relaxed: the put/call ratio at 0.35 is fractionally below its 20-day average of 0.37, and the z-score is flat. There is no defensive hedging ahead of earnings — at least not yet. Overall, positioning looks comfortably bullish rather than cautious or crowded.
Valuation has re-rated alongside the price move. The P/E multiple has compressed modestly — down about 0.27 points over 30 days — reflecting earnings estimates moving up faster than the stock. Price-to-book is running just under 0.91, a relatively modest multiple for a life reinsurer generating double-digit ROE targets. The ORTEX short score holds steady near 32, low and stable, consistent with the absence of short-side pressure. Factor rankings worth noting: the dividend score ranks in the 98th percentile of the universe, though the dividend data in the snapshot is stale and the current yield should be verified independently. Days-to-cover ranks in the 77th percentile and the utilization rank at the 88th percentile — both reflecting how lightly shorted the name is relative to peers.
The earnings track record adds a note of caution to the bullish setup. The last two quarterly prints produced negative next-day moves of roughly 1.6–1.9%, with the weakness persisting through the five-day window. The one exception in recent history was April 30, which produced a small positive day and a follow-through gain of 2.4% over five days. RGA's life-and-health reinsurance mix tends to produce tighter post-earnings ranges than property-catastrophe peers — EG gained 3.4% on the week while MET rose 6.6%, both outpacing RGA's 8.3% weekly gain in the most recent session despite lower correlations. The relatively muted post-earnings history means the August 6 print is likely to turn on specific guidance for Asia Pacific and whether management has stabilised the international benefit ratios that spooked the Street after Q1.
What to watch into August 6: whether the analyst target cluster around $255–$278 prompts incremental institutional buying as the stock approaches those levels, and whether the Asia Pacific headwinds the bear case has flagged show up in preliminary metrics before the formal earnings release.
See the live data behind this article on ORTEX.
Open RGA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Reinsurance Group of America heads into its Q1 2026 earnings report with the analyst community leaning constructively, even as the stock trades at a meaningful discount to consensus targets. The most striking feature…
Reinsurance Group of America heads into its May 7 earnings release with options markets flashing an unusually bullish lean and a sudden, sharp spike in borrowing costs that has yet to translate into meaningful short…
